Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Race for first EBV+ PTLD therapy nears finish line

Race for first EBV+ PTLD therapy nears finish line

New Capabilities

FDA reverses course on pioneering cell therapy, rejecting approval after seven-year development despite no safety concerns

January 13th, 2026: Atara Stock Plummets 53%

Overview

Updated May 20

The FDA rejected tabelecleucel for the second time on January 9, 2026—one day before its scheduled approval decision. The agency reversed its position after five years of dialogue, now claiming the previously accepted ALLELE trial no longer provides sufficient evidence of efficacy due to problems with study design, conduct, and analysis. The companies resolved all manufacturing issues and the FDA raised no safety concerns, but regulators demanded a new study for the first therapy targeting EBV+ post-transplant lymphoproliferative disease.

Atara Biotherapeutics and Pierre Fabre called the decision a "significant and unexpected change" that contradicts extensive prior alignment with the agency. The companies plan to request an urgent Type A meeting within 45 days to find a path forward for accelerated approval. Atara's stock plummeted 53% on the news.

Patients with failed prior therapy—who have life expectancies measured in weeks to months—still have no approved treatment options.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Play on this story Voices Debate Predict Timeline Connections

Key Indicators

2nd
Complete response letter in 12 months
FDA rejected application twice despite resolving manufacturing issues
0
FDA-approved therapies for this disease
No approved treatments exist for EBV+ PTLD after first-line therapy fails
50.7%
Response rate in ALLELE trial
Trial showed significant efficacy but FDA now questions study design
53%
Stock price decline
Atara shares plummeted after second rejection announcement
45 days
Expected Type A meeting timeline
Pierre Fabre expects FDA to grant urgent meeting request within this timeframe

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

Play

Exploring all sides of a story is often best achieved with Play.

Most of these play right now — no account needed. Sign up to save scores, keep a streak, and unlock Debate and Predict. Log in Sign Up
Predict 6 ways this could play out. Back the one you believe — contrarian picks score more when a scenario has a resolution date. Log in to play

People Involved

Pascal Touchon
Pascal Touchon
Former CEO, Atara Biotherapeutics (now Chairman)
Led company through European approval and U.S. regulatory challenges
 Cokey Nguyen, Ph.D.
Cokey Nguyen, Ph.D.
President and CEO, Atara Biotherapeutics
Managing unexpected FDA reversal and planning Type A meeting strategy

Organizations Involved

Atara Biotherapeutics
Atara Biotherapeutics
Biotechnology Company
Stock down 53% after second rejection; relying on Pierre Fabre to navigate FDA path forward

California-based biotech developing allogeneic T-cell immunotherapies for patients with cancer and autoimmune diseases.
Pierre Fabre Pharmaceuticals
Pierre Fabre Pharmaceuticals
Pharmaceutical Company
Planning urgent Type A meeting with FDA after assuming BLA control and receiving second rejection

French pharmaceutical group that acquired global commercialization rights to tabelecleucel through partnership expansion.
FDA Center for Drug Evaluation and Research
FDA Center for Drug Evaluation and Research
Federal Regulatory Agency
Reversed position on ALLELE trial adequacy, requesting new study despite no safety concerns

Federal agency responsible for protecting public health by ensuring safety and efficacy of drugs and biologics.

Timeline

June 2018 January 2026

15 events Latest: January 13th, 2026 · 7 months ago Showing 8 of 15
Tap a bar to jump to that date

  1. Atara Stock Plummets 53%

    Latest Market

    Shares collapse following surprise FDA rejection, raising questions about company's future and path to U.S. commercialization.

  2. Companies Announce Plans for Type A Meeting

    Business

    Pierre Fabre and Atara announce intention to request urgent Type A meeting with FDA to pursue path forward for accelerated approval.

  3. FDA PDUFA Decision Day

    Regulatory

    FDA target action date for tabelecleucel approval decision as first therapy for EBV+ PTLD.

  4. FDA Issues Second Complete Response Letter

    Regulatory

    FDA rejects tabelecleucel BLA, reversing prior acceptance of ALLELE trial and requesting new study despite no safety concerns and resolved manufacturing issues.

  5. BLA Transferred to Pierre Fabre

    Business

    Pierre Fabre assumes full responsibility for U.S. regulatory submission and commercial activities.

  6. FDA Grants Priority Review

    Regulatory

    Agency accepts resubmission with priority review, sets January 10, 2026 PDUFA date.

  7. BLA Resubmitted to FDA

    Regulatory

    Atara and Pierre Fabre resubmit application after resolving manufacturing facility issues.

  8. Clinical Hold Lifted

    Regulatory

    FDA removes clinical hold after reviewing additional finished product data.

  9. FDA Issues Complete Response Letter

    Regulatory

    Agency cites third-party manufacturing facility observations; no clinical or safety deficiencies identified.

  10. FDA Accepts Initial BLA Submission

    Regulatory

    FDA accepts biologics license application for tabelecleucel covering 430+ patients treated.

  11. Global Partnership Expansion

    Business

    Pierre Fabre acquires worldwide commercial rights for up to $640 million plus royalties.

  12. European Commission Approves Ebvallo

    Regulatory

    World's first approval for allogeneic EBV-specific T-cell therapy, marketed as Ebvallo in Europe.

  13. ALLELE Trial Completes Enrollment

    Clinical

    Pivotal trial enrolls 63 patients with relapsed/refractory EBV+ PTLD across global sites.

  14. Pierre Fabre Partnership Announced

    Business

    Atara grants Pierre Fabre European commercial rights for $45 million upfront, up to $320 million total.

  15. ALLELE Pivotal Trial Begins Enrollment

    Clinical

    Phase 3 ALLELE study opens, enrolling EBV+ PTLD patients who failed rituximab or chemotherapy.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

1983-Present

Orphan Drug Act Success in Rare Hematologic Malignancies

Congress passed the Orphan Drug Act in 1983 to incentivize development for diseases affecting fewer than 200,000 Americans. The law provides tax credits, fee waivers, and seven years of market exclusivity. Rare blood cancers became a testing ground, with dozens of orphan drugs approved based on smaller trials and surrogate endpoints rather than traditional large-scale studies.

Then

Hundreds of rare disease therapies reached patients who previously had zero options.

Now

Created sustainable business model for ultra-rare diseases; nearly 40% of new FDA approvals now carry orphan designation.

Why this matters now

Tabelecleucel's orphan and breakthrough designations follow this playbook—FDA accepted a 63-patient trial for a disease with no approved therapies and 50-70% historical mortality.

August-October 2017

Kymriah and Yescarta CAR-T Approvals (2017)

The FDA approved the first two CAR-T cell therapies within two months—Kymriah for pediatric leukemia in August, Yescarta for lymphoma in October. Both were autologous therapies, custom-made from each patient's own T cells. The approvals created an entirely new regulatory category and reimbursement framework with no precedent. Cancer centers scrambled to build infrastructure for treatments costing $373,000-$475,000.

Then

Established regulatory pathway for personalized cell therapies but exposed scalability and access challenges.

Now

Six CAR-T therapies now approved; field shifted focus to allogeneic off-the-shelf approaches to solve manufacturing bottlenecks.

Why this matters now

Tabelecleucel represents the next generation: allogeneic cells from healthy donors, manufactured in batches, potentially solving the supply and speed problems that plagued autologous CAR-T.

2020-2024

Ryoncil Approval After Manufacturing Delays (2024)

Mesoblast's Ryoncil faced years of FDA rejections over manufacturing and chemistry controls before finally winning approval in December 2024 as the first mesenchymal stromal cell therapy for pediatric graft-versus-host disease. The company navigated multiple complete response letters focused entirely on CMC issues, not clinical efficacy.

Then

Four-year delay from initial submission to approval; company nearly collapsed financially waiting.

Now

Created blueprint for resolving manufacturing-based rejections in allogeneic cell therapies.

Why this matters now

Atara's trajectory mirrors Ryoncil—strong clinical data but manufacturing hurdles. The precedent shows FDA will eventually approve if sponsors fix facility issues.

Sources

(17)
+11
CGTlive Atara Biotherapeutics Targeted Oncology PR Newswire PubMed FiercePharma Cancer Network National Cancer Institute Cell & Gene Business Wire Seeking Alpha Benzinga Yahoo Finance Targeted Oncology PR Newswire Cancer Network CGTlive